In an exploratory biomarker analyses the survival benefit from nivolumab (CheckMate-141) was seen regardless of the tumor PD-L1 status, but the magnitude of benefit was greater when tumor PD-L1 expression was ≥1% [17]. The gene discussed is CD274; the disease is neoplasm.